BlinkLab Limited is set to list on the Australian Securities Exchange (ASX) on 4 April 2024 under the ticker code BB1, following an oversubscribed IPO that raised 7m at 0.20 per share.
The company, originating from Princeton University neuroscientists, has developed a smartphone-based diagnostic platform for autism, ADHD, and other neurodevelopmental conditions, leveraging AI and machine learning. The funds from the IPO will support the progression of their autism diagnostic test towards FDA registration, initiate further clinical studies, and enhance their AI/ML algorithms.
BlinkLab's technology, which has shown high accuracy in clinical trials, combines smartphone capabilities with a secure cloud-based platform for data analysis, aiming to improve early diagnosis and treatment outcomes. The company plans to undertake a pivotal registrational study for FDA 510(k) registration and is exploring additional diagnostic tests for conditions like ADHD and schizophrenia.